RecruitingNCT04053439

Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications

A Single Centre Cohort Study to Determine if Clonal Hematopoieses of Indeterminate Potential (CHIP) is a Risk Factor for Chemotherapy-Related Complications in Lymphoma Patients >= 60 Receiving Cytotoxic Chemotherapy

Sponsor

Sunnybrook Health Sciences Centre

Enrollment

188 participants

Start Date

Aug 8, 2019

Study Type

OBSERVATIONAL

Conditions

Chemotherapeutic Toxicity Lymphoma

Summary

'CHIP' stands for Clonal Hematopoiesis of Indeterminate Significance, which are mutations in bone marrow stem cells that give that population of cells a survival or 'clonal' advantage for growth. This study investigates whether CHIP in lymphoma patients aged 60 years and older is a risk factor for chemotherapy-related complications like low blood counts, infections, cardiac events, hospitalizations, dose delays and dose reductions, and failure to recover normal blood counts after chemotherapy finishes.

Eligibility

Min Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study examines whether a condition called clonal hematopoiesis — where a small portion of blood stem cells carry gene mutations (not cancer, but a precancerous change) — increases the risk of serious complications from chemotherapy in patients being treated for lymphoma. **You may be eligible if...** - You have been diagnosed with a lymphoma (such as DLBCL, follicular lymphoma, Hodgkin's lymphoma, CLL, or others listed) - You are starting your first or second line of chemotherapy (with or without rituximab) - You are 18 or older and able to provide a blood sample for testing **You may NOT be eligible if...** - You have already been diagnosed with a myeloid blood cancer - Your circulating white blood cell (lymphocyte) count is significantly elevated - You have other conditions that make participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood test for determination of CHIP

Patients will have one additional blood draw to be sent for DNA extraction and sequencing for CHIP.

Locations(1)

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04053439

Related Trials

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

NCT032236101 location

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

NCT075131291 location

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

NCT073023477 locations

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

NCT054031773 locations

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT052379863 locations